A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy (NCT07249528)

🧪 Interventions in This Study

• Audio Tasks (DIAGNOSTIC_TEST)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Documentation of Disease o Patients must have pathologically confirmed Diagnosed with non-Hodgkin lymphoma or multiple myeloma.
2. Definition of treatment and ability
3. Scheduled to receive an FDA-approved CAR-T product: Axi-cel, Liso-cel, Tisa-cel, Ide-cel, Cilta-cel, or Brexu-cel.
4. Ability to comply with twice daily voice recordings or daily neurologic assessments, as determined by the investigator.
5. Age ≥ 18
6. ECOG Performance Status of ≤ 2
7. Required
8. Perform twice daily voice recordings using a smartphone.
9. Undergo daily neurologic assessments (e.g., ICE score, tremor evaluation).
10. Smartphone ownership.
11. Sufficient English proficiency to complete structured voice tasks in the study application.
12. Comorbid Conditions

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (8 Sites)

• Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
• Memorial Sloan Kettering Monmouth (Consent only) — Middletown, New Jersey
• Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey
• Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) — Commack, New York
• Memorial Sloan Kettering Westchester (Consent only) — Harrison, New York
• Weill Cornell Medical Center (Data Analysis Only) — New York, New York
• Memorial Sloan Kettering Cancer Center (All Protocol Activites) — New York, New York
• Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Rockville Centre, New York

📞 Contact the Study Coordinator

Phone: (646) 888-3483

Email: shouvalr@mskcc.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-hodgkin Lymphoma

• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma — Tucson, Arizona
• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma — Duarte, California
• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) — Houston, Texas
• BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies — Cleveland, Ohio
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies — Mobile, Alabama

Explore by condition: All Non-hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.